A 52 week double blind randomised controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes

Update Il y a 4 ans
Reference: ISRCTN54951661

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Not provided at time of registration


Inclusion criteria

  • Metabolic syndrome, atherosclerosis

Links